Provided by Tiger Fintech (Singapore) Pte. Ltd.

SciSparc Ltd.

0.3080
+0.00220.72%
Post-market: 0.3078-0.0002-0.06%19:57 EDT
Volume:224.17K
Turnover:67.95K
Market Cap:3.46M
PE:-0.29
High:0.3100
Open:0.3100
Low:0.2973
Close:0.3058
Loading ...

SciSparc to Implement 1-for-21 Reverse Stock Split

MT Newswires Live
·
25 Jun

SciSparc Ltd. Announces 1-for-21 Reverse Share Split Effective July 3, 2025

Reuters
·
25 Jun

Scisparc Announces 1-for-21 Reverse Share Split

THOMSON REUTERS
·
25 Jun

SciSparc Ltd. Releases Pro Forma Financials Reflecting Merger with AutoMax Motors

Reuters
·
10 Jun

SciSparc announces publication of Japanese patent application

TIPRANKS
·
27 May

SciSparc Ltd. Announces Japanese Patent for Novel Pain Relief Combination Therapy

Reuters
·
27 May

SciSparc Ltd. Unveils New Compensation Policy for Executive Officers and Directors, Emphasizing Equity-Based Awards and Market-Comparable Benefits

Reuters
·
22 May

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
25 Apr

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

GlobeNewswire
·
25 Apr

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

BRIEF-Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction

Reuters
·
10 Mar

Scisparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

THOMSON REUTERS
·
10 Mar

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

GlobeNewswire
·
10 Mar

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

GlobeNewswire
·
10 Mar

BRIEF-SciSparc Signs Definitive Agreement To Sell Mitocarex

Reuters
·
03 Mar

SciSparc signs definitive agreement to sell MitoCareX to N2OFF

TIPRANKS
·
03 Mar

Scisparc Signs Definitive Agreement to Sell Mitocarex, Computational Drug Discovery Company Targeting Resistant Cancers

THOMSON REUTERS
·
03 Mar

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

GlobeNewswire
·
03 Mar

Scisparc Ltd: on Feb 25, Co Entered Securities Purchase Agreements to Sell, Issue to Debentures in Aggregate Principal Amount of $4.2 Mln

THOMSON REUTERS
·
28 Feb